Loading company…
RougeTx develops small-molecule therapies that target pericytes for rare vascular disorders.
Founded in 2024 and based in Naarden, Netherlands, RougeTx is a biotechnology company. It develops small-molecule therapies that target pericytes, the specialized cells that maintain blood vessel stability and function, for rare vascular disorders. The company is at the Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in